OncoMatch/Clinical Trials/NCT04469764
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Is NCT04469764 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Abemaciclib and Anastrozole for recurrent endometrial carcinoma.
Treatment: Abemaciclib · Anastrozole · Letrozole — This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent ovarian and endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Cancer type
Endometrial Cancer
Ovarian Cancer
Biomarker criteria
Required: CDK4 activation features
demonstrates CDK4/6 activation features
Required: CDK6 activation features
demonstrates CDK4/6 activation features
Excluded: CCNE1 amplification
lack of Cyclin E gene (CCNE) amplification
Excluded: RB1 loss
lack of ... retinoblastoma susceptibility gene product (RB) loss
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: chemotherapy — recurrent ovarian or endometrial cancer
At least one prior chemotherapy regimen for the treatment of recurrent ovarian or endometrial cancer
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 8 g/dL (transfusion permitted, treatment must not begin earlier than the day after transfusion)
Liver function
Total bilirubin ≤ 1.5 x ULN (Gilbert's syndrome: ≤ 2.0 x ULN and direct bilirubin within normal limits); ALT and AST ≤ 3 x ULN
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 8 g/dL ... Total bilirubin ≤ 1.5 x ULN ... ALT and AST ≤ 3 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04469764 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy.
Does this trial require CDK4?
Yes, CDK4 activation features is a required biomarker for enrollment.
Does this trial require CDK6?
Yes, CDK6 activation features is a required biomarker for enrollment.
Are patients with CCNE1 alterations eligible?
No. CCNE1 amplification is an exclusion criterion.
Are patients with RB1 alterations eligible?
No. RB1 loss is an exclusion criterion.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages